Pipeline news

• Epic Sciences and Fulgent Genetics Collaborate to Deliver Definembc™ Results for Metastatic Breast Cancer Patients

  24 February 2022

  

  Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.

• Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

  23 February 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.

• binx health and North Dakota Department of Public Health Partner to Combat the Spread of Sexually Transmitted Infections

  15 February 2022

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient, and the North Dakota Department of Health (NDDoH) are working together to combat the spread and support the treatment of sexually transmitted infections (STIs).

• Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update

  04 February 2022

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced preliminary results from an in vivo study on the M2 metabolite showing that no genotoxicity was found, as measured by formation of micronuclei in the bone marrow or comet morphology in the liver.

• Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials

  30 January 2022

  

  Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).

• Epic Sciences Unveils Definembc™, a Novel Blood-Based Test Designed to Improve Care for Metastatic Breast Cancer Patients

  16 December 2021

  

  Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.

• Epic Sciences Platform Demonstrates Compelling Value of Cell Analysis in Data Presented at San Antonio Breast Cancer Symposium 2021

  15 December 2021

  

  Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.

• binx health Selected as a Top Digital Health Startup that is Transforming the Future of Healthcare -- Named to the 2021 CB Insights Digital Health 150 List

  15 December 2021

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today that CB Insights ranked binx health among the most promising digital health startups in the world.

• Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand

  15 December 2021

  

  Epic Sciences, Inc., developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of experience to the Epic Sciences team.

• binx health and Student Health Insurer, Wellfleet, Expand Agreement in College Health for In-Dorm and At-Home Access to Testing for Sexually Transmitted Infections (STIs)

  09 December 2021

  

  With STIs on the rise, Wellfleet takes leadership role in offering its college partners convenient, accurate, and discreet at-home solutions for sexual health.